Atria Investments buys $4,272,842 stake in Pfizer (PFE)

Pfizer (PFE) : Atria Investments scooped up 30,206 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 128,972 shares of Pfizer which is valued at $4,272,842.Pfizer makes up approximately 0.40% of Atria Investments’s portfolio.

Other Hedge Funds, Including , Hexavest reduced its stake in PFE by selling 489,999 shares or 8.49% in the most recent quarter. The Hedge Fund company now holds 5,283,220 shares of PFE which is valued at $175,033,079. Pfizer makes up approx 3.19% of Hexavest’s portfolio.Jacobs Coca boosted its stake in PFE in the latest quarter, The investment management firm added 2,023 additional shares and now holds a total of 202,775 shares of Pfizer which is valued at $6,815,268. Pfizer makes up approx 1.53% of Jacobs Coca’s portfolio. Maple Securities Usa Inc sold out all of its stake in PFE during the most recent quarter. The investment firm sold 37,579 shares of PFE which is valued $1,263,030.Gillespie Robinson Grimm Inc boosted its stake in PFE in the latest quarter, The investment management firm added 719 additional shares and now holds a total of 11,121 shares of Pfizer which is valued at $373,777. Pfizer makes up approx 0.06% of Gillespie Robinson Grimm Inc’s portfolio.Nadler Financial Group reduced its stake in PFE by selling 236 shares or 0.8% in the most recent quarter. The Hedge Fund company now holds 29,316 shares of PFE which is valued at $983,845. Pfizer makes up approx 0.39% of Nadler Financial Group’s portfolio.

Pfizer closed down -0.48 points or -1.43% at $33.13 with 1,73,32,125 shares getting traded on Tuesday. Post opening the session at $33.56, the shares hit an intraday low of $32.94 and an intraday high of $33.57 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.